GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
B

BrightPath Biotherapeutics Co 4594.T · JPY

Health Care · Tokyo Stock Exchange · 🇯🇵 Japan

Compare

37

0.00%

Close of 9 Nov 2026, in JPY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About BrightPath Biotherapeutics Co

Its shares trade on Tokyo Stock Exchange under the ticker 4594.T. It has been listed since 22 October 2015. In the fiscal year to 31 March 2026, it reported revenue of ¥84,000 and a net loss of ¥1.30bn. At that date it held total assets of ¥2.60bn and shareholders' equity of ¥2.37bn.

BrightPath Biotherapeutics Co., Ltd. engages in the development of cancer peptide vaccines, which constitute one form of cancer immunotherapy. The company is headquartered in Chiyoda-Ku, Tokyo-To. The company went IPO on 2015-10-22. The firm is a biopharmaceutical venture company focused on developing cancer immunotherapeutic. The Companies business model covers drug discovery research and early clinical development of cancer immunotherapy; conducting of early-phase clinical trials; and development, manufacturing, and launching of the drugs as commercial products in Japan and abroad. The firm also generates the revenues from license fees from the pharmaceutical companies.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
22 Oct 2015
Employees
32

Leadership

Pay as last reported

  • Mr. Kenichi NagaiPresident, Chief Executive Officer, Representative Director, since 2009
  • Mr. Yoichi TakeshitaChief Financial Officer, Director, since 2023
  • Dr. Norihiro NakamuraDirector of Drug Discovery Research, CSO, Director, since 2018
  • Dr. Akira YamadaDirector, since 2003
  • Dr. Hirotaka TakeuchiIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • BrightPath Biotherapeutics develops cancer peptide vaccines in the Health Care sector.
  • The company focuses on cancer immunotherapy with 32 employees in Chiyoda-ku.
  • BrightPath generates revenue through license fees from pharmaceutical companies.

Weaknesses

  • BrightPath has only 32 employees, indicating limited workforce capacity.
  • The company's IPO was in 2015, suggesting a relatively young business structure.
  • BrightPath operates in a highly competitive biotechnology industry.

Opportunities

  • Expanding cancer immunotherapy market offers growth potential in Japan and abroad.
  • BrightPath can leverage partnerships with pharmaceutical companies for revenue.
  • The biopharmaceutical venture sector shows increasing investment opportunities.

Threats

  • Biotechnology industry faces regulatory challenges in drug development.
  • Competition from established pharmaceutical firms in cancer immunotherapy.
  • Market volatility may impact biopharmaceutical venture funding.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.